EUVIMEDEUVIMED entdecken
Open Access

Evaluating the Reproductive Impact of Pembrolizumab in Mice: Ovarian Function and Hormonal Changes

Bengü Mutlu Sütcüoğlu, Osman Sütcüoğlu, Betül Öğüt, Orhun Akdoğan, Çağnur Elpen Kodaz, Canan Yilmaz, Özlem Erdem, Elvan Anadol, Nuriye Özdemir

In Vivo · 2026-01 · 40 (1) · 191-201

DOI: 10.21873/invivo.14184 ↗

Kurz gefasst

Fachartikel in der Zeitschrift In Vivo, online erschienen am 02.01.2026. Verfasst von Bengü Mutlu Sütcüoğlu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynaecology, Ankara Atatürk Sanatoryum Research and Training Hospital, Ankara, Türkiye; bengu.sutcuoglu@saglik.gov.tr. Hauptthemen laut MEDLINE: Ovary, Antibodies, Monoclonal, Humanized, Reproduction, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND/AIM: Pembrolizumab, an immune checkpoint inhibitor used in cancer therapy, is associated with immune-related adverse effects, yet its impact on female reproductive health remains unclear. This study aimed to evaluate the effects of pembrolizumab on ovarian function and hormonal balance in a mouse model. MATERIALS AND METHODS: Twenty-four Swiss albino mice were divided into acute and chronic groups, each comprising a pembrolizumab-treated and a saline-control subgroup (n=6 per subgroup). All mice underwent a superovulation protocol, and serum levels of estradiol, follicle-stimulating hormone (FSH), luteinizing hormone (LH), and anti-Müllerian hormone (AMH) were measured using enzyme-linked immunosorbent assay kits. Ovarian tissues were evaluated histologically for follicular counts, including primordial, preantral, and secondary follicles. RESULTS: Estradiol levels were significantly reduced in pembrolizumab-treated mice compared with controls (p=0.007). Significantly higher levels of LH were observed in the chronic control group compared to the chronic pembrolizumab-treated group (p=0.023), while FSH and AMH levels did not differ significantly (p=0.461 and p=0.460, respectively). Primordial follicle counts were significantly higher in control groups than in pembrolizumab-treated groups (p=0.009). CONCLUSION: Pembrolizumab administration in mice led to reduced estradiol levels and diminished primordial follicle counts, indicating potential adverse effects on ovarian reserve. These findings highlight the importance of evaluating reproductive risks in female patients receiving immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OvaryAntibodies, Monoclonal, HumanizedReproductionImmune Checkpoint InhibitorsAnimalsFemaleMiceLuteinizing HormoneAnti-Mullerian HormoneEstradiolFollicle Stimulating HormoneOvarian Follicle

Stichwörter der Autor:innen

Pembrolizumabestradiolfemale fertilityimmune checkpoint inhibitorsovarian reservepreclinical studyreproductive toxicity

Substanzen

pembrolizumabAntibodies, Monoclonal, HumanizedLuteinizing HormoneAnti-Mullerian HormoneEstradiolFollicle Stimulating HormoneImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Obstetrics and Gynaecology, Ankara Atatürk Sanatoryum Research and Training Hospital, Ankara, Türkiye; bengu.sutcuoglu@saglik.gov.tr.
  • Department of Medical Oncology, Gazi University, Ankara, Türkiye.
  • Department of Pathology, Gazi University, Ankara, Türkiye.
  • Department of Family Medicine, Bilecik Şeyh Edabali University, Bilecik, Türkiye.
  • Department of Biochemistry, Gazi University, Ankara, Türkiye.
  • Laboratory Animal Breeding and Experimental Research Center, Gazi University, Ankara, Türkiye.

Zitieren

APA

Sütcüoğlu, B. M., Sütcüoğlu, O., Öğüt, B., Akdoğan, O., Kodaz, Ç. E., Yilmaz, C., Erdem, Ö., Anadol, E., & Özdemir, N. (2026). Evaluating the Reproductive Impact of Pembrolizumab in Mice: Ovarian Function and Hormonal Changes. In Vivo, 40(1), 191-201. https://doi.org/10.21873/invivo.14184

Vancouver

Sütcüoğlu BM, Sütcüoğlu O, Öğüt B, Akdoğan O, Kodaz ÇE, Yilmaz C, et al. Evaluating the Reproductive Impact of Pembrolizumab in Mice: Ovarian Function and Hormonal Changes. In Vivo. 2026;40(1):191-201. doi:10.21873/invivo.14184

BibTeX
@article{Stcolu2026,
  author = {Sütcüoğlu, Bengü Mutlu and Sütcüoğlu, Osman and Öğüt, Betül and Akdoğan, Orhun and Kodaz, Çağnur Elpen and Yilmaz, Canan and Erdem, Özlem and Anadol, Elvan and Özdemir, Nuriye},
  title = {Evaluating the Reproductive Impact of Pembrolizumab in Mice: Ovarian Function and Hormonal Changes},
  journal = {In Vivo},
  year = {2026},
  volume = {40},
  number = {1},
  pages = {191--201},
  doi = {10.21873/invivo.14184}
}
Kostenlos starten →